Biotech firm Cell Signaling Technology has begun applying its proteomics-based antibody discovery platform to human donors, isolating circulating human monoclonal antibodies from plasma.

The technology, which combines mass spec-based proteomics and next-generation sequencing to identify antigen-specific antibody sequences, could prove useful for vaccine research and developing human monoclonal antibodies for therapeutic use, among other applications, CST chief scientific officer Roberto Polakiewicz told ProteoMonitor.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.